← Eichor
Study identifier: NCT06416345 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

Condition: Parkinson Disease  ·  Sponsor: Amsterdam UMC, location VUmc

PhaseNA
Planned participants84
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The majority of people with Parkinson's disease incur Freezing of Gait (FoG), which is not addressed adequately by medication. Cueing is a proven strategy to overcome FoG. The Cue2Walk is a device with automated detection of FoG and provision of rhythmic cues. In this study, the (cost-)effectiveness of the Cue2Walk device as compared to usual care is investigated.

This description comes directly from the study's public registry record.

Talk to the study team

Erwin EH van Wegen, PhD  ·  020-4440461  ·  e.vanwegen@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (2)

RadboudumcNijmegen, Gelderland, NetherlandsNot Yet Recruiting
Amsterdam UMC, location VUmcAmsterdam, North Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06416345